US National OCS Heart Perfusion (OHP) Registry
Launched by TRANSMEDICS · Jun 13, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The OCS Heart Perfusion Registry is a clinical study that aims to gather important information about heart transplants. It is an observational study, meaning that researchers will monitor and collect data from patients who have received a heart transplant, rather than providing a treatment or intervention. This registry is open to individuals of all ages and genders who are undergoing heart transplant procedures.
If you or a loved one is considering a heart transplant, you might be eligible to participate in this study. By joining, participants can help researchers learn more about heart transplant outcomes and improve future care for patients. While there are no specific inclusion or exclusion criteria listed, being part of this registry means you can expect to share your experience and provide valuable information that could benefit others in the future. This trial is currently recruiting participants, and it's a great opportunity to contribute to important research in heart health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • N/A
- Exclusion Criteria:
- • N/A
About Transmedics
TransMedics is a pioneering medical technology company focused on transforming the organ transplant process through innovative solutions. With a commitment to improving patient outcomes, TransMedics has developed advanced organ preservation and transportation systems, notably the Organ Care System (OCS), which enables the preservation and assessment of donor organs in a more physiologically relevant environment. By leveraging cutting-edge technology, TransMedics aims to enhance the viability of organs for transplantation, ultimately expanding the donor pool and improving the lives of patients awaiting transplants. The company’s dedication to research and clinical trials underscores its mission to advance the field of transplantation and contribute to better healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Minneapolis, Minnesota, United States
Boston, Massachusetts, United States
Lexington, Kentucky, United States
Rochester, Minnesota, United States
Charleston, South Carolina, United States
Chicago, Illinois, United States
Boston, Massachusetts, United States
Pittsburgh, Pennsylvania, United States
Valhalla, New York, United States
Durham, North Carolina, United States
Palo Alto, California, United States
Boston, Massachusetts, United States
Seattle, Washington, United States
Seattle, Washington, United States
Tampa, Florida, United States
Atlanta, Georgia, United States
Dallas, Texas, United States
Minneapolis, Minnesota, United States
Jacksonville, Florida, United States
New Haven, Connecticut, United States
Detroit, Michigan, United States
San Francisco, California, United States
New York, New York, United States
Milwaukee, Wisconsin, United States
Milwaukee, Wisconsin, United States
La Jolla, California, United States
Bronx, New York, United States
New York, New York, United States
Charlotte, North Carolina, United States
Ann Arbor, Michigan, United States
Salt Lake City, Utah, United States
Dallas, Texas, United States
Chapel Hill, North Carolina, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported